• unique nature of botanical drugs
  • regulatory policies differ from those for synthetic, semi-synthetic, chemically modified drugs
  • OTC, IND, NDA requirements provided

rare diseasesRARE DISEASE  affects < 200,000 persons in US; most  affect far fewer persons. Guidance addresses  important aspects of drug development:

  • Disease’s natural history
  • Pathophysiology of disease and drug’s proposed mechanism of action
  •  Nonclinical pharmacotoxicology considerations
  • Reliable endpoints and outcome assessment
  • Standard of evidence to establish safety and effectiveness
  • Drug manufacturing considerations during drug development

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account.
Log Out / 
Change )

Google photo

You are commenting using your Google account.
Log Out / 
Change )

Twitter picture

You are commenting using your Twitter account.
Log Out / 
Change )

Facebook photo

You are commenting using your Facebook account.
Log Out / 
Change )

Connecting to %s